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GLP-1S AS SECOND LINE TREATMENT FOR T2DM
ABSTRACT
Type II diabetes mellitus (T2DM) is a prevalent disease in our country. Bullard et al.
(2018) report approximately 21 million adults have T2DM in the United States. “The total
estimated cost of diagnosed diabetes in 2017 is $327 billion, including $237 billion in direct
medical costs and $90 billion in reduced productivity” (Yang et al., 2018). Treatment of T2DM
is individualized to each patient based on their co-morbidities, fiscal responsibility, and route of
administration options. Sulfonylureas and Glucagon-like Peptide-1s (GLP-1) are two classes of
antidiabetic drugs that are available for use as second line treatment options after metformin.
This review of literature is from articles published in 2008 or later found in the following
electronic databases: PubMed, Cochrane Database of Systematic Reviews, DynaMed Plus,
ClincalKey, and Scopus. Articles included randomized control trials, systematic reviews, and
meta analyses with participants being at least eighteen years old. The review found several
benefits of GLP-1s for the treatment of T2DM. The risks of GLP-1s are not found to be as
serious as the risks associated with sulfonylureas. Sulfonylureas demonstrate historical data for
their use and are available in oral forms as opposed to GLP-1s which is newer but in an
injectable form only. Overall, GLP-1s offer greater benefits with minimal side effects that are
less severe than sulfonylureas. Limitations to this literature review include lack of articles
having direct reviews of GLP-1s and sulfonylureas.

Keywords: glucagon-like peptide-1, sulfonylurea, diabetes mellitus, second line
treatment
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INTRODUCTION
The National Institute of Diabetes and Digestive and Kidney Diseases (n.d.) defines type
II diabetes mellitus (T2DM) as a chronic condition that affects the way your body is able to
metabolize glucose. With T2DM, the beta cells within the pancreas are able to produce insulin,
but the body does not respond to the insulin normally or the body is resistant to the effects of
insulin. Insulin is a hormone produced by the pancreas that controls the amount of sugar in the
blood and allows the body to use sugar as a source of fuel. With T2DM, the body is not able to
maintain a normal glucose level which affects multiple other body systems. Since there is no cure
for diabetes, patients will need to control their blood glucose levels with diet and exercise. If that
is not successful, antidiabetic drugs are utilized to supplement the body.
Some of the common antidiabetic drug classes are alpha-glucosidase inhibitors, biguanides
(metformin), DPP-4 inhibitors, glucagon-like peptides (GLP-1), insulin, sodium glucose
transporter 2 inhibitors (SGLT2), sulfonylureas, and thiazolidinediones. Each drug class acts on
the body in a different way to achieve their effects. Due to the difference in mechanisms of actions
of each drug, there are different benefits and risks of the drug classes. The purpose of this review
is to determine if sulfonylureas or GLP-1s offer more benefits while minimizing the adverse effects
for second line treatment of adults with T2DM in the primary care setting. It is anticipated that
the benefits of GLP-1s will outweigh their adverse effects so that GLP-1s can be considered a
superior treatment to sulfonylureas in the second line treatment of adults with T2DM in the primary
care setting.
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Statement of the Problem
With an increasing number of patients getting diagnosed with T2DM and newer drugs
being developed, selecting an appropriate drug that offers the most benefit for the patient can be
overwhelming. Further research is needed to identify which antidiabetic medication effectively
lowers the A1c while providing additional benefits with minimal risks such as hypoglycemia.
Statement of the Research Question
In adult patients with uncontrolled T2DM in the primary care setting, does treatment with
GLP-1s compared to sulfonylureas as adjuvant therapy to metformin offer more benefits while
minimizing adverse effects?
REVIEW OF LITERATURE
Methodology
For this comprehensive review, five electronic databases were searched including
PubMed, Cochrane Database of Systematic Reviews, DynaMed Plus, ClincalKey, and Scopus
from July 14, 2018 to September 21, 2018. Specific terms searched include the following:
sulfonylureas and type 2 AND (Review[ptyp] AND "last 5 years"[PDat]), sulfonylurea AND
GLP1, sulfonylurea AND glucagon-like peptide-1, sulfonylureas AND second line, glucoselowering medications for type 2 diabetes, management of type 2 diabetes in adults, GLP-1, and
sulfonylureas. Works chosen for review were published after the year 2008 and included
randomized controlled trials (RCTs), systematic reviews, and meta analyses. Sources excluded
were those published prior to the year 2008, had poor design study, narrative reviews and studies
that included patients under age eighteen.
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Current Treatment Guidelines for Adults with T2DM
The American Diabetes Association (ADA) produces updated treatment
recommendations after completing intensive evaluation of medical literature and input from the
medical community and American Diabetes Association staff. This is completed on an annual
basis. Their recommendations are graded on an A, B, C, or E level that is representative of the
level of evidence to support the recommendation. A grade A recommendation for A1c goal in
nonpregnant adults is < 7% (American Diabetes Association, 2018). Figure 1 displays treatment
considerations based on the A1c results. The ADA also has a grade A recommendation for
primary treatment of T2DM to be metformin unless it is contraindicated or not tolerated by the
patient. The ADA states “in patients with type 2 diabetes and established arteriosclerotic
cardiovascular disease (ASCVD), antihyperglycemic therapy should begin with lifestyle
management and metformin and subsequently incorporate an agent proven to reduce major
adverse cardiovascular events and cardiovascular mortality (currently empagliflozin and
liraglutide), after considering drug-specific and patient factors” which is a grade A
recommendation (American Diabetes Association, 2018, p. 24). Diabetes is an independent risk
factor for ASCVD in which special consideration is needed when selecting pharmacologic
therapies. Table 1 provides antidiabetic medication options while considering patient specific
conditions for individualized treatment.
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Figure 1. Reprinted from Standards of medical care in diabetes – 2018 abridged for primary
care providers, by American Diabetes Association (2018), retrieved from
http://clinical.diabetesjournals.org/content/36/1/14.full-text.pdf Copyright 2018 by
American Diabetes Association.
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Table 1
Antidiabetic treatment medications and patient considerations for T2DM

Note. Reprinted from Standards of medical care in diabetes – 2018 abridged for primary care
providers, by American Diabetes Association (2018), retrieved from
http://clinical.diabetesjournals.org/content/36/1/14.full-text.pdf Copyright 2018 by
American Diabetes Association.
Dynamed Plus (2018) reports a strong recommendation for adding a second drug if
patients are on the maximum dose of metformin monotherapy and glycemic goals are not met. If
ASCVD is present, adding a drug to reduce major cardiovascular events and mortality such as
empagliflozin or liraglutide (GLP-1) is strongly recommended. If ASCVD is not present and
A1c is not at goal, there is an ADA grade A recommendation for dual therapy which should be
selected based on patient factors and drug characteristics. Antihyperglycemic drug options may
include sulfonylureas, thiazolidinediones, dipeptidyl peptidase IV (DPP-4) inhibitors, sodium
glucose cotransporter-2 inhibitor, glucagon-like peptide-1 receptor agonist, or basal insulin. In
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the Agency for Healthcare Research and Quality (AHRQ) Comparative Effectiveness Review in
2016, 216 studies were reviewed by two reviewers regarding monotherapy and metformin-based
combination therapies to lower the hemoglobin A1c (Maruthur et al., 2016). Combination
therapies that were compared included sulfonylureas and GLP-1s combined with metformin.
Metformin plus exenatide (GLP-1) was the preferred combination to lower the hemoglobin A1c
(based on 3 short duration trials, pooled between group difference 0.26%, 95% CI 0.03%0.48%). When considering body weight, metformin plus a GLP-1 was preferred (based on 4
trials, not pooled due to differences in dosing, drug type, and study duration; range of between
group differences 2.4-12.3 kg). Neither sulfonylureas nor GLP-1s with metformin were
preferred for long-term mortality (Dynamed Plus, 2018).
When adding a second drug to reduce major cardiovascular events and mortality and if
ASCVD is present, GLP-1s such as empagliflozin or liraglutide are strongly recommended by
the ADA (American Diabetes Association, 2018). If ASCVD is not present and A1c is not at
goal, there is an ADA grade A recommendation for dual therapy, which should be selected based
on patient factors and drug characteristics. Antihyperglycemic drug options may include
sulfonylureas, thiazolidinediones, dipeptidyl peptidase IV (DPP-4) inhibitors, sodium glucose
cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, or basal insulin. According
to the Endocrine Society of 2015 as a weak recommendation, adding GLP-1s or SGLT2
inhibitors should be considered when treating patients with T2DM who are overweight or obese
(Apovian et al., 2015).
Montivida, Shaw, Atherton, Stringer, and Paul (2016) utilized the U.S. Centricity
Electronic Medical Records to collect data on the usage of antidiabetic drugs for a longitudinal
exploratory study from 2005 to 2016. This data was collected from primary and ambulatory care

GLP-1S AS SECOND LINE TREATMENT FOR T2DM

11

systems in the United States. This data reports that of the 1,023,340 initially reviewed records of
newly diagnosed T2DM between the ages of 18 and 79 years old, 357,482 records (subcohort 1)
were identified for initiating a second-line medication after metformin. In the subcohort 1,
sulfonylureas were the most popular second-line treatment despite a decrease in usage from 60%
to 46%. GLP-1 usage for second-line treatment increased from 3% in 2006 to 7% in 2016. It
was found that GLP-1 initiation was at the highest body mass index levels of all second-line
treatment options. Montivida et al. noted some limitations to this study that lack of information
on adherence, side effects, dosage changes, socioeconomic status, and insurance type.
Mechanism of Action of Sulfonylureas and GLP-1s
Grøndahl, Keating, Vilsbøll, and Knop (2017) provide information regarding the
mechanism of action of sulfonylureas and GLP-1s. Sulfonylureas bind to the beta cells on the
pancreas to block the KATP channels which increases insulin secretion. An increase in insulin
secretion suppresses the secretion of glucagon leading to decreased blood glucose. GLP-1s bind
to GLP-1 receptors which activates them in order to decrease blood glucose. They are designed
to imitate endogenous GLP-1. Likewise, they are glucose-dependent which improves their
safety.
Table 2 is adapted from an article by Thrasher (2017) that indicates the cellular
mechanism of sulfonylureas is by blocking the KATP channels on the plasma membrane of beta
cells which causes a primary physiologic effect of increasing insulin secretion. Conversely, the
cellular mechanism of GLP-1s works by activating the GLP-1 receptors causing the
physiological effect of increasing insulin secretion, decreasing glucagon secretion, slowing
gastric emptying, and increasing satiety.
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Table 2
Antidiabetic medication class specifics for GLP-1s and SUs

Note. CV = cardiovascular; CVD = cardiovascular disease; GI = gastrointestinal; GLP-1 RA =
glucagon-like peptide-1 receptor agonist; HbA1c = glycated hemoglobin; SC = subcutaneous SU
= sulfonylurea; XR = extended release. Adapted from Pharmacologic approaches to glycemic
treatment, by American Diabetes Association (2017), retrieved from
http://professional.diabetes.org/content/clinical-practice-recommendations Copyright 2017 by
American Diabetes Association.
Kuhn, Park, Ghazi, and Aroda (2017) state that GLP-1 secretion is stimulated by
nutrients entering the small intestine. This results in the insulin synthesis and secretion. The
physiologic effect of slowed gastric emptying and increased satiety results in decreased caloric
intake. A decrease in post-prandial glucose also results. Currently, GLP-1 administration is only
subcutaneous.
Benefits of GLP-1s and Sulfonylureas in the Treatment of Uncontrolled T2DM
Chou et al. (2017) published a meta-analysis that included 40 trials with 70,162
participants on the long-term effects of ischemic heart disease in T2DM. Lower risk of
myocardial infarcts was noted with those taking GLP-1s as compared to those taking
sulfonylureas (OR = 0.48; 95% CI [0.27, 0.91]). There were no significant findings regarding
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the risk of angina or effect on coronary artery disease when taking GLP-1s compared with other
antidiabetic medications or a placebo. GLP-1s have demonstrated the ability to decrease several
cardiovascular risk factors such as body weight, weight circumference, and blood pressure.
These studies were limited to randomized controlled trials available in English. Most trials had
less than one year follow-up.
Courtney, Nayar, Rajeswaran, and Jandhyala (2017) published a review that includes
phase three clinical studies focused on GLP-1s with a duration of at least 76 weeks. The
DURATION-1 study was able to show decrease in A1c (0.4-1.7%) and weight loss (0.9-5.3 kg)
with long term treatment using a GLP-1. The low rate of incidence of hypoglycemia is an
important consideration for long term treatment using an injectable medication. In the studies
reviewed, only 4-21% of those that discontinued treatment of GLP-1s was due to adverse effects.
Adverse effects tend to dissipate with continued treatment. Limitations to this review were due
to the types of studies reviewed and lack of comparison of two GLP-1s.
Courtney et al. (2017) also reported outcomes regarding the cardiovascular benefits of
GLP-1s. One of the studies reviewed was the LEADER trial which happens to be one of the
largest and longest trials investigating the cardiovascular benefits of GLP-1s. This trial is a
phase three, randomized, double-blind, placebo-controlled trial that included 9,340 patients with
a minimum follow-up of 3.5 years. The GLP-1 (liraglutide) was compared against a placebo
which demonstrated cardiovascular benefit from the GLP-1 with fewer deaths from
cardiovascular causes, nonfatal myocardial infarction, or nonfatal strokes (95% CI [0.78, 0.97]; p
= 0.01). Thirty-six months into the trial, the A1c was down by 0.4% in those treated with the
GLP-1 (95% CI [-0.5, -0.3]). Weight loss was down by 2.3 kg more using GLP-1 treatment
(95% CI, [2.0-2.5]).
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The next trial reported by Courtney et al. (2017) was the ELIXA trial which evaluated the
cardiovascular benefits of lixisenatide (GLP-1) in 6,068 T2DM patients. These patients were
diagnosed with a myocardial infarction or hospitalization for unstable angina in the previous 180
days. The trial was a randomized, double-blind, placebo-controlled study with an average
follow-up of 25 months. This trial demonstrated no significant difference in lixisenatide versus
placebo (13.4% vs. 13.2%) regarding cardiovascular death, myocardial infarction, stroke, and
hospitalization for unstable angina (95% CI [0.89-1.17]; p = 0.81). The ELIXA and LEADER
trials demonstrate the differences of pharmacokinetics of the two GLP-1s as the differing results
regarding cardiovascular benefits within the same drug class.
Maruthur et al. (2016) reported a weight loss and decrease in systolic blood pressure by
three to five mmHg without causing an increase in heart rate as benefits of GLP-1s. It is
unknown if these changes in weight and blood pressure are enough to make a difference in the
cardiovascular morbidity and mortality.
Risks of GLP1s and Sulfonylureas in the Treatment of Uncontrolled T2DM
Choby (2017) provided an update regarding pharmacotherapy in T2DM published in the
FP Essentials journal.
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Table 3
Adverse effects of GLP-1s and sulfonylureas
Class/Drug

Average A1c
decrease (%)

Cost

Major Adverse
Effects

Other Adverse
Effects

GLP-1
Exenatide
0.8 - 2
$500 – 520
Nausea, vomiting,
(Byetta, Bydureon)
diarrhea; avoid
with history of
Liraglutide
$769
pancreatitis
(Saxenda, Victoza)
Sulfonylureas
Glimepiride (Amaryl)
0.4 – 1.2
$10 – 70
Hypoglycemia
Weight gain
Glipizide (Glucotrol)
$10 – 30
Glyburide
$10 – 90
Adapted from “Diabetes update: New pharmacotherapy for type 2 diabetes”, by B. Choby,
2017, FP essentials, 456, p. 28-29. Copyright 2017 by AAFP.
As stated in Table 3 from Choby (2017) disadvantages of sulfonylureas are hypoglycemia and
weight gain. Glyburide specifically has increased risks of hypoglycemia and cardiovascular
mortality with long term treatment as compared with other sulfonylureas. Glyburide is not the
recommended to be prescribed to elderly according to the recommendations from the Beers
criteria. In the GLP-1 class, nausea, vomiting, diarrhea, and injection site reactions are some
associated adverse effects. “Risks of increased calcitonin secretion, C-cell hyperplasia, and
medullary thyroid cancer have been linked to sustained GLP-1 receptor activation in mice and
rats” (Choby, 2017, p. 32). Literature suggests that GLP-1s do not have a significant increase in
pancreatic effects, but labels currently recommend avoiding GLP-1s if patients have a history of
pancreatitis and to discontinue use if the patient is diagnosed with pancreatitis while on a GLP-1.
As noted in Table 3, there is a difference in cost associated between GLP-1s and sulfonylureas
with GLP-1s being more expensive.
Douros et al. (2018) completed a population-based cohort study investigating the use of
sulfonylureas as a second line antidiabetic drug and the risk of cardiovascular and hypoglycemic
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events. The study began with 77,138 T2DM patients on metformin. A total of 25,699 patients
added or switched to sulfonylureas. The mean follow-up was limited at 1.1 years. At that time,
sulfonylureas demonstrated an “increased risk of myocardial infarction (incidence rate 7.8 vs. 6.2
per 1000 person years, hazard ratio 1.26, 95% CI [1.01,1.56]), all cause mortality (27.3 vs. 21.5,
hazard ratio 1.28, 95% CI [1.15,1.44]), and severe hypoglycaemia (5.5 vs. 0.7, hazard ratio 7.60,
95% CI [4.64, 12.44]) compared with continuing metformin monotherapy” (p. 1). Table 4 also
identifies the differences from adding a sulfonylurea versus switching to a sulfonylurea.
Table 4
Adverse events when adding or switching to sulfonylureas

Reprinted from “Sulfonylureas as second line drugs in type 2 diabetes and the risk of
cardiovascular and hypoglycaemic events: Population based cohort study”, by A. Douros, S.
Dell’Aniello, O. Yu, K.B. Filion, L. Azoulay and S. Suissa, 2018, BMJ, 362, p. 8. Copyright
2018 by The BMJ.
Limitations to this study include a short duration of follow up and the fact that drug doses were
not considered.
Maruthur et al. (2016) completed a systematic review comparing the safety and
effectiveness of monotherapies and metformin-based combination therapies in adults with
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T2DM. This review consisted of 204 studies with 81% of them being randomized controlled
trials. The studies ranged from three months to eight years with the majority of the studies
lasting less than two years. Participants were overweight or obese and had an A1c of 7-9%.
Safety outcomes were assessed and Maruthur et al. established that sulfonylureas increased the
risk of hypoglycemia as a monotherapy and as a metformin-based combination therapy.
Sulfonylureas were associated with weight gain. Gastrointestinal side effects (nausea, vomiting,
diarrhea) are associated with GLP-1s alone or in combination with metformin more than any
other monotherapy or combination therapy.
Courtney, Nayar, Rajeswaran, and Jandhyala (2017) reported adverse effects of GLP-1s
to include nausea, diarrhea, upper respiratory tract infections, injection site reactions, and
hypoglycemia. Pancreatitis may be associated with the use of GLP-1s. Long term studies of the
risk of pancreatitis in GLP-1 use have not necessarily indicated an increased risk, but it continues
to be monitored.
DISCUSSION
The treatment of T2DM continues to evolve with the new discoveries in treatment with
antidiabetic drugs. Each treatment plan is individualized to the patient’s comorbidities and
preferences and by weighing the benefits and risks. The next section is a discussion of the
review of literature of GLP-1s and sulfonylureas as adjuvant therapy to metformin and it will
highlight the benefits and risks of the therapy.
Despite T2DM being a complex disease, literature does agree on the first line of
treatment to be diet and exercise. If diet and exercise alone are not enough to lower the A1c to
acceptable levels, metformin is the first antidiabetic medication to initiate. If additional adjuvant
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therapy is needed beyond metformin, there are several options which should be selected on an
individual basis.
Chou et al. (2017), Courtney et al. (2017), and Maruthur et al. (2016) all report that the
benefits of GLP-1s include decreasing cardiovascular risk factors of decreasing weight and blood
pressure. Chou et al. and Courtney et al. highlight the cardiovascular benefits of GLP-1s. By
decreasing the risk factors for cardiovascular events, fewer deaths from cardiovascular causes,
nonfatal myocardial infarctions, and nonfatal strokes were reported.
Choby (2017) provides cost information in Table 3 above which supports the idea that
sulfonylureas are more affordable than GLP-1s. Sulfonylureas can cost between $10-90 where
as GLP-1s range from $500 to $769. The affordability of medication plays a role in selecting an
antidiabetic drug for different patient populations.
Currently, sulfonylureas are available as oral medications as opposed to GLP-1s that are
only available in the injectable form. Instead of only daily dosing with GLP-1s, there are options
for once a week dosing as well. The route of administration may affect prescribing patterns
depending on patient preference.
Gastrointestinal side effects are the most commonly reported adverse effects in those who
use GLP-1s. Those side effects may include nausea, vomiting, and diarrhea. It is also
recommended to avoid GLP-1s in anyone with a history of pancreatitis. Choby (2017), Maruthur
et al. (2016) and Courtney et al. (2017) all report gastrointestinal side effects in the studies
reviewed. Courtney et al. also adds an injection site reaction to the list of adverse effects for
GLP-1s and Choby reports on the cost of GLP-1s being a negative effect.
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Choby (2017) and Maruthur et al. (2016) stated hypoglycemia and weight gain as the
most reported adverse effects of sulfonylureas. Douros et al. (2018) indicate an increased risk of
myocardial infarction, all cause mortality, and severe hypoglycemia with sulfonylureas when
compared to metformin monotherapy.
Maruthur et al. (2016) reported on three randomized controlled trials (n = 2,557) with an
odds ratio of 3.4-7.1 and a risk difference of 15-30%. They found that the metformin and GLP-1
combination to be favored over metformin and sulfonylurea combination with a moderate
strength of evidence in supporting effectiveness.
Overall, the review of literature demonstrates benefits of GLP-1s over sulfonylureas. The
adverse effects with GLP-1s may decrease with length of treatment while adverse effects of
sulfonylureas remain unchanged. The cost, gastrointestinal side effects, and the fact that the
GLP-1s are currently only available in an injectable form may be a deterrent for patients.
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APPLICABILITY TO CLINICAL PRACTICE
In clinical practice, T2DM is a diagnosis that is encountered almost daily in the primary
care setting. If it is not in terms of direct treatment, it is seen as a comorbidity in the adult
population. New treatment options continue to be developed to improve the management of
adults with T2DM. Finding the appropriate treatment to manage diabetes can be a challenge.
Between the dosage of medication, class of medication, adverse effects, and affordability of the
medications, it may take multiple clinic visits to be obtain diabetic control before the possibility
of the body changing and needing to find the necessary balance again. This can be very
challenging for the provider and frustrating for the patient.
With this research, it was found that treatment with GLP-1s offer many benefits to T2DM
such as weight loss, low risk of hypoglycemia, decrease in systolic blood pressure, and
cardiovascular protective benefits. These benefits make this injectable medication more
appealing. However, the gastrointestinal side effects are the largest drawback and potentially the
biggest cause for discontinuation of this treatment. The cost and method of administration are
also limitations for this antidiabetic medication for patients.
Sulfonylureas demonstrate solid evidence of their effectiveness in lowering A1c which
strengthens the justification for their continued use as a second line treatment in adults with
T2DM that are not controlled with metformin alone. Due to the established history, there has
been adequate research supporting their use as an antidiabetic medication. The cost is
significantly less for sulfonylureas as compared to GLP-1s. The option of a second line
treatment being an oral form may be more appealing to some patients as compared to an
injectable medication. Sulfonylureas are known to have the potential for weight gain as well as
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hypoglycemia when utilized as a monotherapy and to a less extent as a combination therapy with
metformin.
With the future of genetic research, the potential to predict the effectiveness or lack of
effectiveness of different medications for patients may dramatically change the prescribing
patterns for providers treating T2DM.
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